Clinical Trials Browser

Brentuximab Vedotin × Dermatologic × 1 year × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT07178457 2025-09-17

BeCALM

Phase 3 Not yet recruiting

84 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

NCT05414500 2025-08-08

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Phase 1 Recruiting

10 enrolled

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT03409432 2025-07-25

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Phase 2 Completed

26 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT02616965 2025-04-04

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Phase 1 Completed

16 enrolled

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Clinical Trials

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

BeCALM

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma